BioInvent International AB: Interim Report January-March 2024
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV)
"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs." - Martin Welschof, CEO of BioInvent.
EVENTS IN THE FIRST QUARTER
(R) CASI Pharmaceuticals reported positive interim Phase 1 data for BI-1206 in NHL in China
Supply agreement signed with AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence® (acalabrutinib)
BioInvent regained the rights to immuno-oncology targets from Exelixis
EVENTS AFTER THE END OF THE PERIOD
New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
(R)= Regulatory event
FINANCIAL INFORMATION First quarter 2024
Net sales, SEK 5.9 (16.2) million
Profit/loss after tax, SEK -77.9 (-73.7) million
Profit/loss after tax per share before and after dilution, SEK -1.18 (-1.12)
Cash flow from operating activities, SEK -65.9 (-78.9) million
Liquid funds, current and long-term investments at the end of the period, SEK 1,219.2 (1,546.4) million
About BioInvent BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact: Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0)46 286 85 50 Email: [email protected]
6sense®, the leading platform to revolutionize the way B2B organizations create, manage, and convert pipeline to revenue, today announced the recent appointment of Andy Champion as Senior Vice President of GTM International. Champion's impressive...
Switzerland could further strengthen its reputation as an AI leader following Microsoft's announced plans to add Azure OpenAI services to Swiss data centers, according to a new research report published today by Information Services Group (ISG) , a...
IQAX Ltd., an innovative developer of technology solutions for shipping and logistics based in Hong Kong, announced that Hapag-Lloyd, one of the world's largest container shipping lines, will adopt IQAX eBL to issue electronic bills of lading (eBLs)....
FlagshipTWO, Sweden's second large-scale production facility of green electrofuel (eMethanol), has received the environmental permit for its planned operations in Sundsvall, Sweden. The facility is developed by Liquid Wind and is one of the largest...